

## Correction: Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer



In the original version of this article (1), Ovar3 cell line data in Fig. 2D was a duplicate of the Ovar10 cell line data. This duplication was inadvertent and does not affect the main conclusions of the study. The graph for Ovar3 has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

### Reference

1. Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, et al. Targeting IDH1 as a prosenescent therapy in high-grade serous ovarian cancer. *Mol Cancer Res* 2019;17:1710–20.

---

Published online May 1, 2020.

*Mol Cancer Res* 2020;18:797

doi: 10.1158/1541-7786.MCR-20-0159

©2020 American Association for Cancer Research.